Thelansis

 Invasive pulmonary aspergillosis (IPA) is a severe fungal infection associated with a high mortality rate. The incidence of IPA is on the rise, primarily due to the increasing number of patients undergoing transplants, receiving chemotherapy, and undergoing immunosuppressive therapy. Invasive pulmonary aspergillosis typically manifests in two distinct scenarios: 1.        The classic form of invasive pulmonary aspergillosis occurs as primary pneumonia in patients with profound immunosuppression, such as prolonged neutropenia. This particular presentation has been recognized for many years. 2.        Another common scenario is secondary nosocomial pneumonia, which affects patients admitted to the ICU for other reasons, like ARDS caused by influenza. It is a challenging diagnosis because critically ill patients with superinfections of aspergillus are not usually profoundly immunosuppressed. This superinfection can close...

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection with a high mortality rate. The incidence of IPA is rising due to an increase in the number of patients undergoing transplants and receiving chemotherapy and immunosuppressive therapy. Diagnosis is challenging due to the non-specific nature of symptoms. Voriconazole is the mainstay of treatment. IPA usually occurs in severely immunocompromised patients. Classic at-risk patients with prolonged neutropenia, either due to chemotherapy or immunosuppressive therapy, post hematopoietic stem cell transplant (SCT), or solid organ transplant. ·        The mortality rate of IPA continues to be very high, exceeding 50% in neutropenic patients and 90% in SCT recipients. The competitive landscape of Invasive pulmonary aspergillosis (IPA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with a...